Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Famitinib in Advanced Thyroid Cancer
NCT04521348Phase 2Completed
- Sponsor
- Fudan University
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib, camrelizumab in thyroid cancer, sponsored by Fudan University. Started Dec 2019; status: completed.
02
Drugs
famitinibcamrelizumab
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04521348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521348.